XClose

Brain Sciences

Menu

New facility will revolutionise research into neurological conditions

11 November 2021

UCL President & Provost Dr Michael Spence, Professor Alan Thompson and colleagues explain how the new centre of excellence for UCL Neuroscience will help revolutionise the development of treatments for neurological diseases.

Professor Alan Thompson
UCL is a global leader in pioneering research into neurological diseases and is one of the world's largest, most productive and highest-impact neuroscience centres. The landmark facility at 256 Grays Inn Road will form part of a ‘dual hub’ for UCL neuroscience, supporting our existing laboratories at Queen Square.
 

Watch the video

YouTube Widget Placeholderhttps://www.youtube.com/watch?v=Qy_wDE6T2m0

 

'Breaking ground at a new home for 21st century neuroscience', featuring interviews with:

  • Dr Michael Spence (President & Provost, UCL)
  • Professor Alan Thompson (Pro Vice-Provost for London and Dean of the Faculty of Brain Sciences, UCL)
  • Professor Mike Hanna (Director, UCL Queen Square Institute of Neurology)
  • Dr Hélène Crutzen (Manager, UCL Queen Square Institute of Neurology)
  • Professor Linda Greensmith (Professor of Neuroscience, UCL)
  • Dr Adrian Ivinson (Chief Operating Officer, UK DRI)
  • Dr Chris Turner (Divisional Clinical Director, National Hospital for Neurology and Neurosurgery)
  • Kevin Argent (Director of Estates Development, UCL)

The state-of-the-art facilities will be home to three bodies: the world-leading UCL Queen Square Institute of Neurology; the headquarters of the UK Dementia Research Institute, which is the single biggest investment the UK has ever made in dementia; and the UCLH National Hospital for Neurology and Neurosurgery (NHNN), which is the UK's largest dedicated neurological and neurosurgical hospital.

It will bring together research scientists, clinicians and patients to create a world-class research and treatment environment for conditions including dementia, Alzheimer’s disease, multiple sclerosis, Huntington’s disease, neuromuscular diseases, Parkinson’s disease, motor neuron diseases, stroke and epilepsy.

UCL signed a contract with construction partner ISG to deliver the 17,500m2 state-of-the-art new neuroscience facility, and demolition and construction are now underway with the building due to be completed in 2024.

Earlier this year UCL’s President & Provost was joined by ISG and University College London Hospitals NHS Foundation Trust to break ground at the site on Grays Inn Road.

Related

Related News